skip to Main Content

Triple Combination of Therapies Shows Promise in Pancreatic Cancer Trial

Newsfeed image, light gray text on dark gray background

BioLineRx Ltd. has revealed that stage IV pancreatic ductal adenocarcinoma (PDAC) patients treated with the triple combination of motixafortide (BL-8040), KEYTRUDA® (pembrolizumab) and chemotherapy in its COMBAT/KEYNOTE-202 clinical study had a meaningful improvement in their overall and progression free survival.

The triple combination study arm enrolled a total of 43 patients initially diagnosed with unresectable stage IV metastatic PDAC, who had progressed following first-line gemcitabine-based therapy. Read more . . . 


Back To Top